Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aplastic anemia associated with interferon beta-1a.

Ahmad Kamal Aslam1, Tajveer Singh

  • 1Department of Internal Medicine, Long Island College Hospital, Brooklyn, New York, USA. dr_kamal@hotmail.com

American Journal of Therapeutics
|November 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prosthetic heart valves: types and echocardiographic evaluation.

International journal of cardiology·2007
Same author

Hypothermia: evaluation, electrocardiographic manifestations, and management.

The American journal of medicine·2006
Same author

Primary lymphedema tarda in an 88-year-old African-American male.

Journal of the National Medical Association·2005
Same author

Cardiac effects of acute myelitis.

International journal of cardiology·2005
Same author

Fatal splenic sequestration crisis with multiorgan failure in an adult woman with sickle cell-beta+ thalassemia.

The American journal of the medical sciences·2005

Subcutaneous interferon beta-1a treats relapsing multiple sclerosis and may improve cognition. A rare case of aplastic anemia associated with this treatment in a multiple sclerosis patient is reported.

Area of Science:

  • Neuroimmunology
  • Hematology

Background:

  • Subcutaneous interferon beta-1a is a standard treatment for relapsing multiple sclerosis (MS).
  • It is known to modulate immune responses and may improve cognitive function in MS patients.
  • Potential side effects include flu-like symptoms and neutralizing antibodies; rare concerns exist regarding acute demyelination.

Observation:

  • A case report details a multiple sclerosis patient who developed aplastic anemia.
  • This rare adverse event occurred during treatment with subcutaneous interferon beta-1a.
  • The patient underwent thorough hematologic evaluation to exclude other causes.

Findings:

  • The development of aplastic anemia was suspected to be associated with interferon beta-1a therapy.
  • While mild anemia was observed in clinical trials, aplastic anemia is an unprecedented finding.

Related Experiment Videos

  • This case highlights a potential, albeit rare, severe hematologic complication.

    • Implications:

    • This case suggests a need for vigilance regarding potential severe hematologic adverse events with interferon beta-1a.
    • Further investigation may be warranted to understand the mechanism linking interferon beta-1a to aplastic anemia.
    • Clinicians should consider this rare possibility in multiple sclerosis patients presenting with unexplained cytopenias.